Journal
PHARMACOGENOMICS
Volume 17, Issue 5, Pages 489-498Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs.16.2
Keywords
HLA; IFN-beta; multiple sclerosis
Categories
Funding
- Hamadan University of Medical Sciences [1394.475]
- Day Medical Laboratory, Hamadan, Iran
Ask authors/readers for more resources
Aims: This study investigated the influence of HLA class-I and -II genes in the response to IFN-beta in relapsing-remitting multiple sclerosis (MS) patients. Patients & methods: In this cohort, 231 relapsing-remitting MS patients who are classified into IFN-beta responders (n = 146) and nonresponders (n = 85) and 180 ethnic-matched healthy controls were analyzed. Clinical outcome of IFN-beta therapy particularly Expanded Disability Status Scale scores were evaluated in relation to HLA-A, -B and -DRB1 alleles and haplotypes. Results: Increased frequencies of HLA-DRB1*04 allele and HLA-A*03-B*44-DRB1*04 haplotype, and decreased frequency of HLA-B*15 were associated with better response to IFN-beta treatment. Conclusion: The possibility of genetic screening particularly HLA typing prior to starting IFN-beta therapy for MS may permit the identification of likely responders or nonresponders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available